October 14, 2022Intravenous ketamine infusions could effectively reduce symptoms in patients with treatment-resistant depression (TRD), suicidal ideation (SI), and anxiety, according to a new study published in the Journal of Clinical Psychiatry.
The study analyzed data from 424 TRD patients who received ketamine injections from November 2017 to May 2021. 1Patients received six ketamine infusions at a starting dose of 0.5 mg/kg, each one lasting around 40 minutes.
Half of the patients responded to treatment within six weeks, and 20% reported remission of their depression symptoms. (After 10 infusions, response and remission rates for depression were 72% and 38%, respectively.) During the same period, 50% of patients with self-harm/suicidal ideation reported entering remission or had fewer symptoms.Read more on additudemag.com